Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.

Dheur MS, Poirel HA, Ameye G, Tilman G, Saussoy P, Defour JP, Camboni A, Van Den Neste E, Coulie PG, van Baren N.

Leuk Lymphoma. 2019 Apr;60(4):1043-1052. doi: 10.1080/10428194.2018.1508663. Epub 2018 Oct 2.

PMID:
30277098
2.

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.

Zhu J, Powis de Tenbossche CG, Cané S, Colau D, van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljeström P, Uyttenhove C, Van den Eynde BJ.

Nat Commun. 2017 Nov 10;8(1):1404. doi: 10.1038/s41467-017-00784-1.

3.

Highly Aggressive Metastatic Melanoma Cells Unable to Maintain Telomere Length.

Viceconte N, Dheur MS, Majerova E, Pierreux CE, Baurain JF, van Baren N, Decottignies A.

Cell Rep. 2017 Jun 20;19(12):2529-2543. doi: 10.1016/j.celrep.2017.05.046.

4.

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.

Seremet T, Koch A, Jansen Y, Schreuer M, Wilgenhof S, Del Marmol V, Liènard D, Thielemans K, Schats K, Kockx M, Van Criekinge W, Coulie PG, De Meyer T, van Baren N, Neyns B.

J Transl Med. 2016 Aug 2;14(1):232. doi: 10.1186/s12967-016-0990-x.

5.

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.

Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, Thielemans K, Neyns B.

J Clin Oncol. 2016 Apr 20;34(12):1330-8. doi: 10.1200/JCO.2015.63.4121. Epub 2016 Feb 29.

PMID:
26926680
6.

Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.

Bosisio FM, Wilmott JS, Volders N, Mercier M, Wouters J, Stas M, Blokx WA, Massi D, Thompson JF, Scolyer RA, van Baren N, van den Oord JJ.

Mod Pathol. 2016 Apr;29(4):347-58. doi: 10.1038/modpathol.2016.28. Epub 2016 Feb 12.

7.

Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan.

van Baren N, Van den Eynde BJ.

Cancer Immunol Res. 2015 Sep;3(9):978-85. doi: 10.1158/2326-6066.CIR-15-0095. Epub 2015 Aug 12. Review.

8.

Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance.

Vigneron N, van Baren N, Van den Eynde BJ.

Oncoimmunology. 2015 Feb 3;4(5):e1003012. eCollection 2015 May.

9.

Tryptophan-degrading enzymes in tumoral immune resistance.

van Baren N, Van den Eynde BJ.

Front Immunol. 2015 Feb 3;6:34. doi: 10.3389/fimmu.2015.00034. eCollection 2015. Review.

10.

Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues.

Théate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C, Van den Eynde BJ.

Cancer Immunol Res. 2015 Feb;3(2):161-72. doi: 10.1158/2326-6066.CIR-14-0137. Epub 2014 Sep 30.

11.

A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors.

Loriot A, Van Tongelen A, Blanco J, Klaessens S, Cannuyer J, van Baren N, Decottignies A, De Smet C.

Epigenetics. 2014 Aug;9(8):1163-71. doi: 10.4161/epi.29628. Epub 2014 Jul 8.

12.

Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy.

Bourdeaux C, Lurquin C, Jacquemart I, Lethé B, Brasseur F, van Baren N, Baurain JF, Dyson J, Van Snick J, Uyttenhove C, Boon T.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3502-7. doi: 10.1073/pnas.1401115111. Epub 2014 Feb 18.

13.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS.

Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21.

14.

Characterization of the T cell response in allergic contact dermatitis caused by corticosteroids.

Baeck M, Soria A, Marot L, Theate I, Hendrickx E, Van Belle A, Goossens A, Tennstedt D, Dachelet C, Jaeger J, Pilette C, Renauld JC, Van Baren N, Rozières A, Nicolas JF, Dumoutier L.

Contact Dermatitis. 2013 Jun;68(6):357-68. doi: 10.1111/cod.12040.

PMID:
23692036
15.

Ongoing adaptive immune responses in the microenvironment of melanoma metastases.

van Baren N, Coulie PG.

Ann N Y Acad Sci. 2013 May;1284:62-5. doi: 10.1111/nyas.12093.

PMID:
23651195
16.

Lymphoid neogenesis in melanoma: What does it tell us?

van Baren N, Baurain JF, Coulie PG.

Oncoimmunology. 2013 Jan 1;2(1):e22505.

17.

Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases.

Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N.

Cancer Res. 2012 Aug 15;72(16):3997-4007. Epub 2012 Jul 31.

18.

A synopsis of serum biomarkers in cutaneous melanoma patients.

Vereecken P, Cornelis F, Van Baren N, Vandersleyen V, Baurain JF.

Dermatol Res Pract. 2012;2012:260643. doi: 10.1155/2012/260643. Epub 2012 Jan 12.

19.

DNA methylation profiling reveals a predominant immune component in breast cancers.

Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothé F, Rouas G, Metzger O, Majjaj S, Saini K, Putmans P, Hames G, van Baren N, Coulie PG, Piccart M, Sotiriou C, Fuks F.

EMBO Mol Med. 2011 Dec;3(12):726-41. doi: 10.1002/emmm.201100801. Epub 2011 Nov 16.

20.

Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples.

Lucas S, van Baren N, de Smet C, Coulie PG.

Int J Cancer. 2012 Apr 15;130(8):1960-6. doi: 10.1002/ijc.26198. Epub 2011 Aug 2.

21.

Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?

Cipponi A, Wieers G, van Baren N, Coulie PG.

Cancer Immunol Immunother. 2011 Aug;60(8):1153-60. doi: 10.1007/s00262-011-1026-2. Epub 2011 May 7. Review.

PMID:
21553145
22.

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG.

Cancer Res. 2011 Feb 15;71(4):1253-62. doi: 10.1158/0008-5472.CAN-10-2693. Epub 2011 Jan 7.

23.

Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens.

Kholmanskikh O, van Baren N, Brasseur F, Ottaviani S, Vanacker J, Arts N, van der Bruggen P, Coulie P, De Plaen E.

Int J Cancer. 2010 Oct 1;127(7):1625-36. doi: 10.1002/ijc.25182.

24.

[General principles and first clinical trials of therapeutic vaccines against cancer].

Baurain JF, Van der Bruggen P, Van den Eynde BJ, Coulie PG, Van Baren N.

Bull Cancer. 2008 Mar;95(3):327-35. doi: 10.1684/bdc.2008.0588. Review. French.

25.

Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.

Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D.

J Immunol. 2008 Mar 1;180(5):3585-93.

26.
27.

Defining the prognostic value for galectin-3 in cutaneous melanoma.

Vereecken P, Ghanem G, Morandini R, Suciu S, Van Baren N, Heenen M.

J Int Med Res. 2007 Sep-Oct;35(5):731-2. No abstract available.

PMID:
17900410
28.

Is serum galectin-3 a potential predictor of the response to active specific immunotherapy in melanoma patients?

Vereecken P, Heenen M, Babar S, Van Baren N.

J Eur Acad Dermatol Venereol. 2007 Feb;21(2):278-80. No abstract available.

PMID:
17243984
29.

Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1.

Hanagiri T, van Baren N, Neyns B, Boon T, Coulie PG.

Cancer Immunol Immunother. 2006 Feb;55(2):178-84. Epub 2005 Sep 27.

PMID:
16187089
30.

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T.

J Clin Oncol. 2005 Dec 10;23(35):9008-21. Epub 2005 Aug 1.

PMID:
16061912
31.

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M.

Int J Cancer. 2005 Nov 20;117(4):596-604.

32.

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

Lurquin C, Lethé B, De Plaen E, Corbière V, Théate I, van Baren N, Coulie PG, Boon T.

J Exp Med. 2005 Jan 17;201(2):249-57.

33.

Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.

Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T.

Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14631-8. Epub 2004 Sep 27.

34.

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

Liénard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE.

Cancer Immun. 2004 May 19;4:4.

35.

Abundant expression of fibronectin is a major feature of leukemic dendritic cells differentiated from patients with acute myeloid leukemia.

Vialle-Castellano A, Gaugler B, Mohty M, Isnardon D, van Baren N, Olive D.

Leukemia. 2004 Mar;18(3):426-33.

PMID:
14737076
36.

A gene expressed exclusively in acute B lymphoblastic leukemias.

Vialle-Castellano A, Laduron S, De Plaen E, Jost E, Dupont S, Ameye G, Michaux L, Coulie P, Olive D, Boon T, van Baren N.

Genomics. 2004 Jan;83(1):85-94.

PMID:
14667812
37.

Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.

Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethé B, Connerotte T, Corbière V, Demoitié MA, Liénard D, Dréno B, Velu T, Boon T, Coulie PG.

J Immunol. 2003 Nov 1;171(9):4898-904.

38.

Immunosurveillance against cancer and immunotherapy--synergy or antagonism?

Boon T, van Baren N.

N Engl J Med. 2003 Jan 16;348(3):252-4. No abstract available.

PMID:
12529468
39.

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.

Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G.

Eur J Cancer. 2003 Jan;39(1):70-7.

PMID:
12504661
40.

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T.

Immunol Rev. 2002 Oct;188:33-42. Review.

PMID:
12445279
41.

Peptide-based cancer vaccines.

Machiels JP, van Baren N, Marchand M.

Semin Oncol. 2002 Oct;29(5):494-502. Review.

PMID:
12407514
42.

Biological and clinical developments in melanoma vaccines.

Marchand M, Brichard V, van Baren N, Coulie PG.

Expert Opin Biol Ther. 2001 May;1(3):497-510. Review.

PMID:
11727521
43.

MAGE-A genes are not expressed in human leukemias.

Chambost H, van Baren N, Brasseur F, Olive D.

Leukemia. 2001 Nov;15(11):1769-71.

44.

Expression of gene MAGE-A4 in Reed-Sternberg cells.

Chambost H, Van Baren N, Brasseur F, Godelaine D, Xerri L, Landi SJ, Theate I, Plumas J, Spagnoli GC, Michel G, Coulie PG, Olive D.

Blood. 2000 Jun 1;95(11):3530-3.

PMID:
10828039
45.

High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene.

Baurain JF, Colau D, van Baren N, Landry C, Martelange V, Vikkula M, Boon T, Coulie PG.

J Immunol. 2000 Jun 1;164(11):6057-66.

46.

Genes encoding tumor-specific antigens are expressed in human myeloma cells.

van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, André M, Ravoet C, Doyen C, Spagnoli GC, Bakkus M, Thielemans K, Boon T.

Blood. 1999 Aug 15;94(4):1156-64.

PMID:
10438702
47.

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.

Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Liénard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jäger E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T.

Int J Cancer. 1999 Jan 18;80(2):219-30.

48.

Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides.

Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jiménez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, Boon T, Garrido F.

Tissue Antigens. 1998 Dec;52(6):520-9.

PMID:
9894850
49.

PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells.

van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG.

Br J Haematol. 1998 Sep;102(5):1376-9.

PMID:
9753074
50.

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.

Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG.

Immunity. 1997 Feb;6(2):199-208.

Supplemental Content

Loading ...
Support Center